

(EUR)	31/12/2024	31/12/2023
Assets		
Fixed assets	30 176,20	37 118,83
III. Tangible fixed assets	26 776,20	33 718,83
B. Plant, machinery and equipment	26 776,20	33 470,16
C. Furniture and vehicles	0,00	248,67
IV. Financial fixed assets	3 400,00	3 400,00
C. Other financial fixed assets	3 400,00	3 400,00
2. Amounts receivable and cash guarantees	3 400,00	3 400,00
Current assets	797 006,59	932 781,72
VII. Amounts receivable within one year	5 000,00	5 000,00
B. Other amounts receivable	5 000,00	5 000,00
IX. Cash at bank and in hand	721 749,14	911 931,72
X. Accruals and deferred income	70 257,45	15 850,00
Total assets	827 182,79	969 900,55
Equity and liabilities		
Equity	719 456,54	923 176,02
III. Reserves	76 776,20	83 470,16
A. Reserves not available	76 776,20	83 470,16
4. Other	76 776,20	83 470,16
IV. Accumulated profits (+)/ losses (-)	642 680,34	839 705,86
Amounts payable	107 726,25	46 724,53
IX. Amounts payable within one year	39 413,22	29 724,53
C. Trade debts	16 444,51	5 701,49
1. Suppliers	16 444,51	5 701,49
E. Taxes, remuneration and social security	22 968,71	24 023,04
1. Taxes	4 413,15	12 349,03
2. Remuneration and social security	18 555,56	11 674,01
X. Accruals and deferred income	68 313,03	17 000,00
Total liabilities	827 182,79	969 900,55
Profit and loss account		
I. Operating income	865 881,53	870 277,66
A. Turnover	864 726,33	869 802,42
D. Other operating income	1 155,20	475,24
II. Operating charges	1 081 773,74	768 735,84
A. Goods for resale, raw materials and consumables	748 686,61	504 522,94
1. Purchases	748 686,61	504 522,94

B. Services and other goods	180 971,69	175 932,29
C. Remunerations, social security costs and pensions	143 815,59	78 993,13
D. Amortisations of and other amounts written down on formation expenses, intangible and tangible fixed assets	6 942,63	6 953,64
G. Other operating charges	1 357,22	2 333,84
III. Operating profit/loss	-215 892,21	101 541,82
IV. Financial income	24 217,79	8 919,08
A. Income from financial fixed assets	425,37	242,92
C. Other financial income	23 792,42	8 676,16
V. Financial charges	12 045,06	18 516,98
A. Debt charges	350,20	2 806,48
C. Other financial charges	11 694,86	15 710,50
VI. Profit/loss of the period before taxes	-203 719,48	91 943,92
IX. Profit/loss of the period	-203 719,48	91 943,92
X. Transfer from/to untaxed reserves	6 693,96	20 081,84
A. Transfer from untaxed reserves	6 693,96	20 081,84
XI. Profit/loss of the period available for appropriation	-197 025,52	112 025,76
Appropriation account	0,00	0,00
A. Profit/loss to be appropriated	642 680,34	839 705,86
1. Profit/Loss of the period available for appropriation	-197 025,52	112 025,76
2. Profits/loss of the preceding period brought forward	839 705,86	727 680,10
D. Profit/loss to be carried forward	642 680,34	839 705,86
1. Profit to be carried forward	-642 680,34	-839 705,86

REVENUE 2024				
INDUSTRY related				
AstraZeneca	40.000,00 €	7%		
BI	175.650,00 €	29%		
Boston Scientific	6.000,00 €	1%		
Bayer	17.000,00 €	3%		
CymaBay	22.000,00 €	4%		
Echosens	10.000,00 €	2%		
Gilead	90.000,00 €	15%		
IPSEN	25.000,00 €	4%		
Genfit	18.700,00 €	3%		
Mirum	4.650,00 €	1%		
Norgine	7.000,00 €	1%		
Novonordisk	143.500,00 €	24%		
Takeda	18.020,20 €	3%		
Roche	30.000,00 €	5%		
TOTAL	607.520,20 €	100%	70%	
NON INDUSTRY related				
EU PROJECTS				
ARTEMIS	96.176,70 €	37%		
HL4EU	14.525,00 €	6%		
Liverscreen	9.201,46 €	4%		
GripOnMASH	10.500,00 €	4%		
THRIVE	59.237,50 €	23%		
Microb-Predict	6.227,64 €	2%		
Liveraim	16.875,00 €	7%		
Liverhope	18.268,16 €	7%		
Genial	12.734,78 €	5%		
MEMBERSHIP	0	0		
OTHER	13.459,89 €	5%		
TOTAL	257.206,13 €	100%	30%	
TOTAL	864.726,33 €			100%